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Abstract.  We report that a  subpopulation (10%) of the 
Mac-1  (CDllb/CD18) molecules on activated neutro- 
phils mediates adhesion to ICAM-1  and fibrinogen. 
We describe a  novel mAb (CBRM1/5) that binds to an 
activation-specific neoepitope on a  subset of Mac-1 
molecules on neutrophils and monocytes after stimula- 
tion with chemoattractants or phorbol esters but does 
not recognize Mac-1 on resting myeloid cells. 
CBRM1/5 immunoprecipitates a  subpopulation of 
Mac-1  molecules from detergent lysates of neutrophils, 
binds to immunoaffinity-purified Mac-l, and localizes 
to the I domain on the u  chain of Mac-1.  Because 
CBRM1/5 recognizes a  fraction of Mac-1  on activated 
neutrophils, but still blocks Mac-l-dependent adhesion 
to fibrinogen and ICAM-1,  we suggest that only a 
small subset of Mac-1  molecules is competent to 
mediate adhesion. 
U 
'NDER normal conditions, circulating neutrophils flow 
through the vascular system making few attachments 
to the endothelium. Within minutes of an exposure 
to an inflammatory stimulus, neutrophils roll along the adja- 
cent vessel wall, adhere firmly to the endothelium, and then 
traffic into the parenchyma (8).  Recent experiments have 
identified the molecules on neutrophil and endothelial cell 
surfaces that facilitate emigration. Members of the selectin 
family mediate the initial rolling (47, 48, 82) and members 
of  the integrin family strengthen neutrophil attachment to the 
endothelium (47, 82),  and then promote transmigration to 
the underlying tissue (7,  72). 
The subfamily ofintegrins that mediates neutrophil attach- 
ment to endothelium includes three members, LFA-1 (CD1  la/ 
CD18),  Mac-1  (CDllb/CD18),  and p150,95  (CDllc/CD18) 
which share a common ~  subunit that is noncovalently as- 
sociated with unique but closely related ct chains (42,  74). 
These leukocyte integrins mediate several additional adhe- 
sive  events that are  crucial  for immune system function. 
They promote the adhesion that is required for T lymphocyte 
target cell lysis (15), T lymphocyte  proliferation (15), natural 
killing  (43),  lymphocyte and  monocyte adhesion  to  en- 
dothelial cells (25,  36, 83), neutrophil homotypic aggrega- 
tion, and neutrophil chemotaxis (6). 
Experiments by several groups have demonstrated that the 
adhesiveness of the leukocyte integrins is not constitutive, 
but rather is controlled by intracellular signals transduced 
from other surface receptors. For example, LFA-1 on resting 
T  lymphocytes is  unable  to  bind to  its  counter-receptor 
ICAM-1 until a signal has been delivered through the antigen 
receptor (26, 78).  The signal to adhere is transient, in that 
within 30 min of stimulation, T lymphocytes lose their abil- 
ity to bind ICAM-1. Similarly, Mac-1 on neutrophils does not 
bind its cellular or soluble ligands including ICAM-1 (20), 
fibrinogen (4, 86), factor X (3), or iC3b (84) until a specific 
signal (e.g., chemotactic factor, cytokine, or phorbol ester) 
has been delivered;  stimulation increases the avidity of Mac-1 
for its ligands within seconds (6,  11,  17,  84). 
While it is clear that activation facilitates leukocyte inte- 
grin interaction with ligand, the molecular mechanism for 
the change in avidity remains poorly understood. Because 
there is no increase in LFA-1 expression after antigen stimu- 
lation or  phorbol  ester  treatment in  T  cells,  the  avidity 
change of LFA-1 for ICAM-1 is believed to occur because of 
a structural change in the molecule (26).  Alternatively, the 
change in avidity could stem from a signal to cluster adhe- 
sion receptors at the cell surface (16). The mechanism for 
avidity regulation of  Mac-1 on neutrophils appears analogous 
but the analysis is complicated by a  greater than  10-fold 
quantitative increase in expression that follows stimulation 
(10, 17, 49, 55, 76).  However, the change in surface expres- 
sion that occurs after stimulation does not parallel the ki- 
netics or magnitude of adhesion (11, 49), as ion channel an- 
tagonists (80) or temperature conditions (66) that inhibit the 
quantitative increase in Mac-1 expression do not block Mac- 
1-dependent adhesion to endothelial cells or in vitro sub- 
strates. Thus, Mac-1 is hypothesized to undergo additional 
conformational changes that facilitate adhesion (11, 49, 59, 
80).  Studies showing that divalent cations (1, 21, 23, 79) or 
mAbs against Mac-1 or LFA-1 (22, 38, 40, 61) augment adhe- 
sion in the absence of activation, support a model in which 
direct structural changes to the extracellular regions regulate 
leukocyte integrin avidity. 
If  avidity  regulation  translates  into  a  conformational 
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it should be possible to generate probes that sense only the 
inactive or  active  states  of the  molecule.  Indeed,  mAbs 
against the platelet integrin gplIb-IIIa have been described 
that react with only activated and not resting platelets (57, 
68).  In this report,  we describe the generation of a  novel 
mAb that reacts with Mac-1 molecules on activated neutro- 
phils, purified Mac-1 substrates, or detergent-solubilized cell 
lysates. Because CBRM1/5  binds to a  subset (10-30%)  of 
Mac-1 molecules on stimulated neutrophils, but still blocks 
binding to fibrinogen and ICAM-1, we suggest that an acti- 
vated subset of Mac-1 molecules mediates adhesion. 
Materials and Methods 
Monoclonal Antibodies 
The following  murine mAbs against human antigens were used: TS1/22 
(anti-CD1 la, IgG1, ascites) (64); LM2/I (anti-CD1 lb, IgG1, protein A-puri- 
fied)  (55);  CBRMF23  (anti-CDllb,  IgG2a,  protein  A-purified)  (20a); 
OKM1 (anti-CD1 lb, IgG2b, protein A-purified) (85); LPMI9c (anti-CDllb, 
IgG2a,  a gift of Dr.  K.  Pulford,  Radcliffe  Hospital, Oxford,  UK) (77); 
BLY6 (anti-CDllc, IgG1, ascites) (77); R6.5 (anti-CD54,  IgG2a, generous 
gift  of  Dr.  R.  Rothlein,  Boehringer-Ingelheim, Ridgefield,  CT)  (72); 
(CBRIC1/ll (anti-CD54,  lgGl, protein A-purified) (M. S.  Diamond and 
T. A. Springer, unpublished data); and My4 (anti-CD14,  IgG2b, purified) 
(34) (Coulter Immunology, Hialeah, FL). X63 (nonbinding antibody, IgG1) 
and 3G8 (anti-CD16,  IgG1) (29) were used as culture supernatants. 
Protein Purification 
Mac-1 was purified from leukocyte lysates by immunoaffinity chromatogra- 
phy after detergent solubilization  as previously  described (20).  Soluble 
ICAM-1 (sICAM-1, generous gift of Dr.  S. Marlin, Boehringer-Ingelheim 
Pharmaceuticals, Ridgefield, CT) was purified from supernatants of ICAM-1 
transfected CHO cells by immunoaflinity chromatography as previously de- 
scribed (51). 
Tissue Culture, Transfection, and Cell Preparation 
Nentrophils were isolated from the whole blood of healthy volunteers by 
dextran sedimentation at room temperature with FicoU gradient centrifuga- 
tion and hypotonic lysis at 4~  as previously  described (28,  55).  Before 
12SI-mAb binding experiments,  neutrophils (2  ￿  107 cells/ml) were stored 
at 4~  in HBSS,  10 mM Hepes,  pH 7.3,  1 mM MgC12, 1 mM CaC12 
(HHMC) 1 in polypropylene  tubes (Falcon 2097,  Becton Dickinson, Lin- 
coln Park, N J). For time course and temperature studies, the leukocyte-rich 
supernatant was used after dextran sedimentation. Cell suspensions were 
placed on ice immediately  and washed  four times to remove platelets  in 
HBSS,  10 mM Hepes,  pH 7.3, and resuspended at 5  ￿  106 cells/ml in 
HHMC.  Neutrophils were identified during flow cytometry by forward and 
90  ~ scatter,  and confirmed by immunostaining with a  mAb to  CD16. 
Mononuclear cells were isolated  from the interface of the Ficoll gradient 
and washed  five times in RPM1  1640, 5  mM EDTA,  2.5%  FCS (heat- 
inactivated,  low endotoxin, Hyclone Laboratories, Inc., Logan,  UT), and 
resuspended in L15, 2.5%  FCS,  1 mg/rnl  human -/-globulin  (ICN  Im- 
munoBiologicals,  Costa Mesa, CA) at 5  ￿  106 cells/ml at 4~  Mono- 
nuclear cells were immunostained according to the protocol for neutrophils 
(see below). The monocyte subpopulation was determined by the flow cyto- 
metric forward and 90  ~ scatter pattern and confirmed by immunostaining 
with the mAb to the monocyte-specific  CD14 antigen. 
The generation and selection of CHO cells expressing wild-type and chi- 
meric forms of Mac-1 and p150,95 will be described (20a). They were main- 
1. Abbreviations used in this paper: fMLP, f-met-leu-phe;  HHMC,  HBSS, 
10 mM Hepes,  pH 7.3, 1 mM MgCI2,  1 mM CaCI2. 
tained  in  tx-MEM,  10%  dialyzed  FCS,  16  pM  thymidine,  0.05  /zM 
methotrexate,  2 mM glutamine, and 50 pg/ml gentamicin. 
Generation and Labeling of CBRM1/5 IgG and 
Fab Fragments 
The generation of mAbs against Mac-1 will be described in detail elsewhere 
(20a). In brief, hybridomas were prepared from BALB/c mice that were im- 
munized with  immnnoattinity-purified  Mac-1. Hybridomas  (500)  were 
screened as follows. Purified neutrophils were isolated,  separated into two 
groups, and preincubated at 37"C for 5 min in HHMC.  One population was 
treated with phorbol esters (PMA, 100 ng/ml) for 10 rain whereas the other 
remained untreated. Cell suspensions were placed on ice for 5 min, in- 
cubated with hybridoma supernatants, and processed by flow cytometry. In 
some cases, neutrophils were fixed with 2 % paraformaidehyde  before incu- 
bation with mAbs. CBRM1/5 was identified  for its ability to bind PMA- 
stimulated but not resting neutrophils.  It was cloned twice by limiting dilu- 
tion, and purified from culture supernatant by protein A-Sepharose affinity 
chromatography after NI-hSO4 precipitation (35).  CBRM1/5 was  deter- 
mined to be of the IgG1 subclass (ImmunoPure Monoclonal Antibody Iso- 
typing Kit, Pierce Chemical  Co., Rockford, IL). 
Fab fragmentation of CBRM1/5 was performed by pepsin digestion fol- 
lowed by cysteine reduction (58). Fal:r were separated by 1.5 x 75-cm S-200 
Sephacryl  (Pharmacia Molecular Biology Division, Piscataway, NJ) size- 
exclusion chromatography.  Fallelnted from the column as a single homoge- 
neous peak with an apparent Mr of 40,000.  Purity of Fall2 and Fall frag- 
ments was confirmed by reducing (5 % B-mercaptoethanol)  and nonreducing 
(50 mM iodoacetamide)  8 % SDS-PAGE. Proteins were visualized by silver 
staining (56).  Unlabeled (Bio-Rad Laboratories, Richmond, CA) or ~*C- 
labeled (Gibco BRL, Gaithersburg,  MD) protein standards included myosin 
(200,000 Mr),/~-gaiactosidase  (116,000 Mr), phosphorylase B (97,000 Mr), 
serum albumin (66,000 Mr), ovalbumin  (43,000 Mr), carbonic anhydrase 
(31,000 Mr), trypsin inhibitor (21,500 Mr), and lysozyme  (14,000 Mr). 
mAbs (100 #g) were labeled with Na1251 (1 mCi) using 1,3,4,6-tetra- 
chloro-3ct, 6tx-diphenylglycouril (Pierce Chemical Co.) (30). The specific 
activity of the iodinated mAbs was determined (protein recovery averaged 
83 #gs; sp act 6-7  x  106 cproJp.g). 
12sI-mAb Binding Assays 
Purified neutrophils (2  ￿  107 cells/rnl in HHMC) were either kept on ice 
or warmed  to 37~  for 5 rain and stimulated  (PMA,  100 ng/ml; fMLE 
10-TM) for 10 rain. Activated neutrophils  were immediately  placed on ice 
and 500,000  ceils were aliquoted  into u-bottom plates  (96-well nontissue 
culture-treated  microtiter  plates,  Linbro-Titertek,  Flow  Laboratories, 
McLean,  VA)  containing increasing concentrations of  iodinated  mAb 
(0.109-112 nM) in the absence or presence of 20-100-fold excess cold mAb. 
The binding media contained L15, 2.5% FCS,  1 mg/ml human `/-globulin. 
Neutrophils were incubated with iodinated mAbs for 4 h on ice, washed five 
times with L15, 2.5% FCS by 21-gauge needle aspiration,  lysed with L15, 
2.5% FCS, 0.2 N NaOH, and counted for `/-emission.  Specific binding was 
determined by subtracting the cpm in the presence of excess cold mAb. 
Scatchard  plots  were generated (65)  and site densities were  determined 
using the data point at which there was no additional increase in specific 
binding of labeled mAb. 
Surface Labeling, Immunoprecipitation, and 
Gel Electrophoresis 
Purified  neutrophils (2  ￿  10  7 cells)  were  washed  twice in PBS,  1 mM 
MgC12, 0.5  mM CaCl2,  and resuspended  in 2 ml; fMLP (10  -7 M) was 
added to some aiiquots of neutrophils.  The cells were iodinated,  lysed, and 
precleared  as previously  described (20). 
Immunoprecipitations  were performed one of two ways: (a) indirectly by 
incubating 250 ~1 of mAb (neat supernatant or 20 pg/ml purified IgG) with 
1/xl of 1 mg/rnl-purified rabbit anti-mouse IgG (Zymed Laboratories, Inc., 
South San Francisco,  CA) for 4 h at 4~  Protein A-Sepharose (20 pl of 
a 1:1 slurry) was added for overnight incubation. Eppendorf tubes were can- 
trifuged,  supernatants were aspirated, 50 pl of iodinated  neutrophil lysate 
was added, and the mixture was incubated for 2 h at 4~  while shaking 
vigorously;  or (b) directly by adding 60 #1 of a 1:4 diluted lysate to 60 #1 
of directly coupled mAb-Sepharose (2-3 mg purified  mAb per milliliter 
CNBr-activated-Sepharose CL-4B) and incubated for 2  h  at 4~  while 
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previously been described (20). Samples were loaded and subjected to 7 % 
SDS-PAGE  (44)  in  the  presence of /3-mercaptoethanol,  and  autoradi- 
ographed with intensifying screens (46). 
Preclearing experiments were performed with directly coupled-Sepha- 
rose as follows. After the initial immunoprecipitation with control (mouse 
IgG) or specific Sepharose (LM2/1, CBRM1/5), the beads were pelleted, 
the supernatant (60 #1) transferred to a second aliquot of the same rnAb- 
Sepharose, and incubated as described above. Subsequently, these beads 
were pelleted, the supernatants (60 #l) transferred to an aliquot of either 
LM2/1 or CBRM1/5-Sepharose, and incubated. After each round of immu- 
noprecipitation, the beads were washed and the bound protein eluted as pre- 
viously described (20).  Samples were loaded and subjected to 5%  SDS- 
PAGE (44) in the presence of/3-mercaptoethanol and autoradiography (46). 
ELISA with Purified Mac-1 
Immunoattinity-purified human Mac-1  was diluted  1:20 in 25  mM Tris- 
HC1,  150 mM NaC1,  2 mM MgC12, and adsorbed to individual wells of 
a nontissue culture-treated microtiter plate (Linbro-Titertek, Flow Labora- 
tories) for 1 h at 37"C. Plates were washed five times and blocked for 1 h 
at 37~  in HHMC supplemented with 1% human serum albumin. Plates 
were then washed twice with HBSS, 10 mM Hepes, pH 7.3, 10 mM EDTA, 
0.05% Tween 20 and twice again with HBSS, 10 mM Hepes, pH 7.3, 0.05% 
Tween 20. mAb solution (100/~1 of 20 #g/mi of purified mAbs) in HBSS, 
10 mM Hepes, pH 7.3, 0.05%  Tween 20 supplemented with either 1 mM 
MgC12,  1 mM CaClz,  1 mM MnCIz or 5  mM EDTA (HHTcation) was 
added to the wells and allowed to incubate for 1 h at 37~  The plates subse- 
quently were iced for 5 rain and washed four times with HHTcation at 4~ 
Enzyme-linked second antibody (50  /~1 of 1:400  dilution of HRP  goat 
anti-mouse IgG (Zymed Laboratories Inc.) was added in HHTcation, in- 
cubated for 1 h at 4~  and the plates were washed five times with HHTcat- 
ion at 4~  Substrate (2,2-azino-di(3-ethylbenzthiazoline) sulfonic acid) 
(Zymed Laboratories, Inc.) was added in 0.1 M citrate with 0.05%  H202, 
and the results quantitated at 414 nm on an ELISA plate reader (Titertek 
Multiscan MCC340, Flow Laboratories). 
Flow Cytometry Studies 
The time course and temperature studies were performed as follows. After 
dextran sedimentation, purified neutrophils or leukocyte-rich supernatants 
(5  x  106 cells/mi in HHMC) were preincubated in 1.5-ml Eppendorf tubes 
at 0, 25, or 37~  for 5 rain before stimulus was added (IL-8, 25 ng/ml [72- 
amino acid form], PeproTech, Rocky Hill, NJ; fMLP, 10-7M;  PMA, 100 
ng/ml). After a time point was reached, samples were placed on ice immedi- 
ately and aliquots were added to individual wells of a u-bottom microtiter 
plate on ice containing mAb. In some cases, after a time point was reached, 
cells were fixed immediately with paraformaldehyde (2 %) and incubated for 
30 min on ice. Immunofluorescence and flow cytometry were performed as 
described (19). The protocol for conversion of  logarithmic fluorescence into 
fluorescence has been described (67). 
Adhesion Assays 
Purified fibrinogen (2 mg/mi in PBS [Sigma Chemical Co., St. Louis, MO]) 
or purified slCAM-1 (200 ~g/mi in PBS) were spotted (25 #1) onto 6-cm 
bacterial Petri dishes (Fisher 1007) for 90 min at room temperature. Plates 
were blocked with the detergent Tween 20 as previously described (20). 
Neutrophils (4  x  106 ceils in 1 mi) were resuspended in HBSS,  10 mM 
Hepes, pH 7.3,  1 mM MgCI2,  and preincubated with mAbs for 10 min at 
room temperature. Subsequently, cells were added to the dishes in the pres- 
ence or absence of fMLP (10  -7 M, final vol of 3 mi), and allowed to adhere 
for 4 min. Nonadherent ceils were removed by 12 washes with a Pasteur 
pipette after gentle swirling with the same buffer supplemented with 0.5% 
BSA. Binding was quantitated by scoring the number of adherent cells of 
at least four different fields using an ocular grid at 100￿  magnification. The 
percent inhibition by mAb was determined upon comparison with the media 
control. 
The binding of ICAM-1 §  L  cells is a  modification of previously de- 
scribed protocols (19). Briefly, purified Mac-1 was diluted and adsorbed (30 
/xl) to 6-cm Petri dishes. After a 90-min incubation at room temperature, 
nonspecific binding sites were blocked with 0.5% heat-treated BSA. After 
removal from tissue culture plates with trypsin-EDTA (Gibco Laboratories, 
Inc.,  Grand  Island,  NY),  ICAM-1 +  L  ceils  were  washed  twice  and 
resuspended in PBS, 2 mM MgCI2, 0.5% heat-treated BSA (0.5-1.0  ￿  106 
cells/ml). 30 min before the binding assay,  the Petri dishes or cells were 
preincubated at room temperature with rnAb (1:200 dilution of ascites or 
20 #g/ml of purified mAb) in PBS, 2 mM MgCI2, 0.5% heat-treated BSA 
(2 ml). Cells (1 ml) were added to Petri dishes, and incubated for 60 rain 
at 37~  The Petri dishes were then swirled and nonadherent cells were re- 
moved by tipping the plate at an angle, removing the binding buffer with 
a Pasteur pipette, and adding fresh media (3 nal) to the edge of the dish. 
The procedure was repeated five times. Subsequently, the number of adher- 
ent cells was determined by light microscopy at 100x using an ocular grid. 
The percent binding was normalized to a media control. 
Results 
Monoclonal Antibody to a Neoepitope on Mac-1 
If a  conformational change in Mac-1  was involved in the 
regulation of its adhesiveness, specific epitopes should be 
expressed on activated but not resulting ceils. To generate 
mAbs that recognize these activation-dependent epitopes, 
immunoaflinity-purified Mac-1  that was judged functional 
by its capacity to bind several ligands (18, 19) was used to 
immunize  BALB/c  mice.  Hybridoma  supernatants  were 
screened for their differential ability to bind to resting and 
phorbol ester-activated neutrophils. One mAb, CBRM1/5, 
showed little binding to resting neutrophils but bound to neu- 
trophils that were stimulated with phorbol esters (Fig. 1 A). 
CBRM1/5  bound to activated cells at a significantly lower 
level compared to previously characterized mAbs to Mac-1. 
Immunoprecipitation  from  detergent  lysates  of  surface- 
labeled neutrophils (Fig. 1 B) or transfected COS ceils (data 
not shown) confirmed that CBRM1/5  recognized Mac-1. 
The lower level of expression of the CBRM1/5 epitope on 
PMA-stimulated  neutrophils  was  not  due  to  insufficient 
amounts of mAb, as studies by flow cytometry suggested that 
saturation was reached at 20/zg/ml (data not shown). This 
was confirmed by binding experiments with ~25I-CBRM1/5 
and ~25I-LM2/1. CBRM1/5  bound specifically to activated 
(fMLP or PMA) neutrophils but not to resting neutrophils 
(Fig. 2 A and C, note difference in scale; Table I). Despite 
the lower absolute numbers of binding sites, the binding of 
CBRM1/5 was saturable, and of comparable affinity (K~ = 
15  nM) to LM2/1  (Kd  =  2  nM).  Neutrophils  stimulated 
with fMLP or PMA had a total Mac-1 site density of 139,000 
and  197,000  sites/cell  (determined  with  LM2/1)  but  a 
CBRM1/5  neoepitope site density of 13,000-57,000  sites/ 
cell, respectively (Table I). Bivalent binding of CBRM1/5 to 
Mac-1  was not strictly required because monovalent Fab' 
fragments of CBRM1/5 bound specifically to activated neu- 
trophils  and  displaced  (Ki  of Fab'  =  200  nM)  bivalent 
CBRM1/5  IgG (Fig. 2 E, and data not shown). 
Kinetics and Temperature Studies 
IL-8, fMLP, or PMA prompted a time-dependent increase 
in expression of the CBRM1/5  epitope that plateaued after 
10 min (Fig. 3). In all cases, CBRM1/5 reacted with a subset 
of the LM2/1-reactive Mac-1 molecules on the cell surface. 
rnAb binding studies were carded out at different  tempera- 
tures to determine whether the CBRM1/5 epitope expression 
correlated with an increase in surface expression or the acti- 
vation of Mac-1 (Fig. 4). Elevating the temperature from 4 
to 37~  increases the surface expression of Mac-1 but does 
not necessarily promote Mac-l-dependent adhesion (11, 49, 
66).  This  temperature-dependent  increase  is  primed  by 
Diamond  and Springer A Subset of Mac-1 Binds to ICAM-1 and Fibrinogen  547 Figure L (A) Immunofluorescence flow cytometry  of  peripheral blood neutrophils that were unstimulated or treated with PMA (100 ng/ml) 
for 10 min at 37~  Neutrophils were stained with either a negative control (X63), a mAb to Mac-1 tx subunit (LM2/1), or CBRM1/5. 
(B) Immunoprecipitation of Mac-I from Triton-X-100 detergent lysates of ~25I-labeled  peripheral blood neutrophils. Immunoprecipitates 
with the following  mAbs were subjected to reducing 5% SDS-PAGE  and autoradiography: lane 1, CBRIC2/2 (ICAM-2, as control, neutro- 
phils are negative for ICAM-2); lane 2, LM2/1 (Mac-1 t~); lane 3, CBRM1/5 (Mac-1 c0. Molecular weights of protein standards (see 
Methods) are indicated to the left. 
preparative procedures. We found that raising the tempera- 
ture  from  4  to  37~  significantly  increased  the  overall 
amount of surface Mac-l, whereas expression of the CBRM1/5 
epitope remained virtually absent on both monocytes (Fig. 
4 A) and neutrophils (Fig. 4 B). In contrast, in both mono- 
cytes and  neutrophils,  fMLP triggered expression of the 
CBRM1/5 epitope. These experiments suggest that the ex- 
pression of CBRM1/5  is associated with the activation of 
Mac-1. 
Epitope Mapping of CBRM1/5 on Transfected Cells 
We examined the expression of CBRM1/5 on CHO cells that 
were transfected with wild-type and chimeric Mac-1  mole- 
cules (Fig. 5). A subset of Mac-1  molecules on transfected 
CHO cells constitutively expressed the CBRM1/5 epitope. 
This agrees with our previous observations that the activa- 
tion mAb NKI-L16 reacted constitutively with a  subset of 
LFA-1 molecules on transfected COS cells (45).  CHO cell 
transfectants that express wild-type Mac-1  are functional in 
that  they  rosetted  with  iC3b-coated  erythrocytes, bound 
Leishmania promastigotes, and adhered to purified ICAM-1 
(data not shown).  CBRM1/5 localized specifically to the I 
domain of the Mac-1  ot chain as it,  like LM2/1, bound to 
CHO cells that expressed the wild-type Mac-1 and chimera 
X-e-M-b-X  which  contains  the  I  domain  of Mac-1  on  a 
p150,95 frame. In contrast, CBRM1/5 did not bind to wild- 
type p150,95  or the reciprocal chimera, M-e-X-b-X, which 
contains a p150,95 1 domain on a Mac-1 backbone (Fig. 5). 
Effect of Divalent Cations on CBRM1/5 Expression 
For integrins to bind to their ligands, divalent cations are re- 
quired. Adhesion is abolished uniformly by the presence of 
EDTA and altered quantitatively by the type of divalent cat- 
ion that is present (1,  18, 23, 33). We tested the CBRM1/5 
and LM2/1 epitopes for their sensitivity to different divalent 
cations.  For binding to cell surface (Fig.  6 A) or purified 
Mac-1  (Fig. 6 B), the presence of divalent cations was re- 
quired for CBRM1/5 epitope expression but not for LM2/I. 
5  mM  EDffA abrogated the expression of CBRM1/5  but 
only  slightly  reduced  expression  of  LM2/1.  Neutrophils 
stimulated with fMLP expressed the neoepitope better in the 
presence of Ca  2§ than in Mg  2§ alone, but in other studies, 
CBRM1/5  was  expressed better on neutrophils  stimulated 
with PMA in the presence of Mg  2§ alone (data not shown). 
Mn  2+, which is reported to enhance Mac-1  adhesive func- 
tion in vitro (1), augmented the expression of CBRM1/5 on 
purified Mac-1  and promoted the expression of the epitope 
on  resting  neutrophils.  Unlike  the  Mac-1  on neutrophils, 
Mac-1 that was purified by immunoaffinity chromatography 
expressed equivalent levels of the CBRM1/5 and LM2/1 epi- 
topes in the presence of divalent cations. In contrast, Mac-1 
that was purified by iC3b-Sepharose chromatography (37) 
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Figure 2. Binding of CBRM1/5 IgG and Fab'. Saturation binding to 
A, neutrophils that were stimulated  with PMA (100 ng/ml)  for  10 
min at 370C.  and  C, untreated neutrophils.  Neutrophils  were in- 
cubated  with  nSI-labeled  CBRM1/5  either  in the absence  (o)  or 
presence of excess unlabeled  CBRM1/5  (zx) for 4 h on ice. Specific 
binding  (e) was measured by subtracting the nonspecific  from the 
total binding.  (B) A Scatchard plot of the specific  binding from the 
I.  t~_ 
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260  460  600  860  1600 
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1200 
curve in panel  A.  The calculated  I~  is  15  nM.  The x-intercept 
(1010 pM) is equivalent to 60,800 sites per neutrophil. (E) Competi- 
tion of I~I-CBRM1/5  IgG  by CBRM1/5  Fab' fragments.  Neutro- 
phils  that had been stimulated  with PMA (100 ng/ml)  for 10 min 
at 37~  and fixed  with paraformaldehyde  were incubated  with a 
subsaturating concentration  of 12sI-CBRM1/5 IgG  (1  nM) and in- 
creasing  concentrations  of unlabeled  CBRM1/5  Fab' fragments  for 
60 min at 37~  Bars indicate  the standard error of the mean for 
triplicates.  (D)  8%  SDS-PAGE  of  IgG  and  Fab  fragments  of 
CBRM1/5.  Samples (3-5  /zg) of CBRM1/5  IgG  (lanes  1  and 4), 
CBRM1/5  Fab'2 (lanes 2 and 5), or CBRM1/5  Fab' (lanes  3 and 5) 
were subjected to 8%-SDS-PAGE  under nonreducing  (50 mM io- 
doacetamide,  lanes 1-3) or reducing (5 %/~-mercaptoethanol,  lanes 
4-6) conditions  and silver  staining.  Molecular weights  of protein 
standards (see Methods)  under  nonreducing  and reducing  condi- 
tions are indicated  in the center. 
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z251-LM2/1  t:5I-CBRM 1/5 
Sites/Cell  Sites/Cell 
Unstimulated  11,300  5:1,600  -900  5:900 
fMLP  138,700  5:21,000  13,200  +  1,400 
PMA  196,900  •  800  57,200  +  1,300 
The site densities were determined from the amount of rnAb bound at satura- 
tion.  Data (+ standard error of the mean) are the average of two independent 
experiments performed  in triplicate on a single donor. 
expressed the LM2/1 epitope but lacked the CBRM1/5 epi- 
tope, and was unable to sustain ligand binding (Diamond, 
M. S., K. P. M. van Kessel, S. D. Wright, and T. A. Springer, 
unpublished observations). 
A 
Structural Subsets of  Mac-1 
To  determine  whether  CBRM1/5  recognized a  subset  of 
Mac-1  molecules,  sequential  immunoprecipitation experi- 
ments were performed (Fig. 7). After preclearing a neutro-  B 
phil lysate twice with CBRM1/5-Sepharose so that negligible 
amounts  of CBRM1/5-reactive  Mac-1  remained,  LM2/1- 
Sepharose  immunoprecipitated  a  significant  quantity  of 
Mac-1.  However, if the lysate was precleared with LM2/1- 
Sepharose first, CBRM1/5-Sepharose was unable to immu- 
noprecipitate any additional Mac-1.  These experiments sug- 
gest that CBRM1/5 recognizes a subset of  the LM2/1-reactive 
Mac-1 molecules in the cell lysate. Close examination of the  ,~ 
immunoprecipitates revealed that the amount of Mac-1 that 
expressed the CBRM1/5 epitope in solution exceeded that on  ~. 
the surface of activated neutrophils. Detergent solubilization 
may remove physical or chemical constraints on Mac-1 and 
prompt some molecules to acquire spontaneous expression 
of the CBRM1/5 epitope. In support of this, immunoaffinity- 
purified Mac-1 (Fig. 6 B) and detergent-permeabilized, rest- 
ing neutrophils both express CBRM1/5 (data not shown). 
Functional Effects of CBRM1/5 
To determine whether the subset of Mac-1 molecules identi- 
fied by CBRM1/5 was functionally important, we examined 
the ability of this mAb to block Mac-I-dependent neutrophil 
adhesion to ICAM-1. Adhesion of  neutrophils to ICAM-1 has 
been shown previously to depend both on Mac-1 and LFA-1 
(20,  71). Bivalent IgG, Fab'2, or monovalent Fab' fragments 
of CBRM1/5 inhibited greater than 80% of  the Mac-l-depen- 
dent  binding  of tMLP-stimulated  neutrophils  to  ICAM-1 
(Fig.  8 A).  CBRM1/5  was  comparable in effectiveness to 
LPM19c, a mAb to Mac-1  that binds a  similar number of 
sites per cell as LM2/1 and completely  blocks Mac-I-ICAM-1 
interaction (Fig. 8 A, [19],  and data not shown). As a con- 
trol, a third mAb to Mac-l, CBRM1/23, had no significant 
inhibitory effect on neutrophil adhesion to ICAM-1.  When 
CBRM1/5 was added to a blocking mAb to LFA-1 (TS1/22), 
similar to the case with LPM19c (20), the combination of 
mAbs  virtually  abolished  neutrophil binding  to ICAM-1. 
The ability of CBRM1/5 to inhibit Mac-l-dependent neutro- 
phil interaction with ICAM-1  was confirmed in binding as- 
says  with  purified  Mac-1  (Fig.  8  B).  Preincubation  of 
purified Mac-1  with CBRM1/5 completely abolished adhe- 
sion of L ceils transfected with ICAM-1. 
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Figure 3. Kinetics of  expression of  Mac-I epitopes. Neutrophils that 
were activated at 37~  for the indicated times with no stimuli (open 
triangles), fMLP (10-TM, solid squares), IL-8 (25 ng/ml, solid 
circles), or PMA (100 ng/ml, open circles) were immunostained 
with A, CBRM1/5 or B, LM2/1 and subjected to immunofluores- 
cence flow cytometry. Data are expressed as relative linear fluores- 
cence units and represent the mean of three experiments. The bars 
indicate the standard error of the mean. 
We also examined the effect  of  CBRM1/5 on Mac-1 binding 
to a second ligand, fibrinogen. The binding of neutrophils 
that are stimulated with fMLP to fibrinogen has been shown 
to be mediated by Mac-1 (86). CBRM1/5 almost completely 
abolished fMLP-stimulated neutrophil adhesion to purified 
fibrinogen (Fig. 8 C). CBRM1/5 IgG and Fab' blocked adhe- 
sion to fibrinogen "o90%, and half-maximal blocking was 
observed at  "~0.5  #g/ml  and  10  /zg/ml  of IgG  and  Fab', 
respectively  (Fig.  8  C).  Again,  other  mAbs  to  Mac-1 
(CBRM1/23) used at similar concentrations showed little in- 
hibitory effect (data not shown).  Thus, the  10%  subset of 
Mac-1 molecules on neutrophils after fMLP stimulation that 
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Figure 4. The effect  of temperature on Mac-1 expression on A, pe- 
ripheral blood monocytes and B, neutrophils. Cells were incubated 
at 4, 25, and 37~  in the absence or presence of stimuli (fMLP, 
10-TM; PMA,  100 ng/ml) for 10 min, and then immunostained 
with either a negative control (X63), a mAb to Mac-1 a  subunit 
(LM2/1), or CBRM1/5. Representative histograms show the log 
fluorescence intensity versus cell number. 
is identified by CBRM1/5 mediates at least 90 % of the adhe- 
sive activity of Mac-1. 
Discussion 
We have characterized a novel mAb, CBRM1/5,  that binds 
to a subpopulation of Mac-1 molecules on activated but not 
resting peripheral blood neutrophils and monocytes. This 
mAb  recognizes  an  activation-dependent neoepitope  and 
acts as  a  reporter  for the activation state of Mac-1.  Our 
results demonstrate that the subset of Mac-1 molecules that 
express the CBRM1/5 neoepitope mediates adhesion to at 
least two of its characterized ligands, ICAM-1 and fibrino- 
gen. Evidence for this includes the following: (a) CBRM1/5 
does not react by immunofluorescence with Mac-1  on the 
surface of resting neutrophils or monocytes. However, stim- 
ulation with the chemoattractant fMLP, the chemoattractive 
cytokine IL-8, or phorbol esters rapidly promotes expression 
of the epitope on a  subset of Mac-1  molecules. The time 
course of expression of the neoepitope and adhesive activity 
of Mac-1 (6, 17) are parallel as both occur within 2 min. (b) 
The quantitation of site densities by saturation binding ex- 
periments  with  ~25I-labeled mAbs to  Mac-1  demonstrates 
that resting neutrophils express  ~12,000  LM2/1  binding 
sites per cell but no specific CBRM1/5 sites per cell. Treat- 
ment with fMLP and PMA increases the overall site density 
of Mac-1 (as reported by LM2/1) greater than 10-fold as has 
been previously described (10, 49, 55, 76), and induces ex- 
pression of the CBRM1/5 neoepitope on 10-30%  of these 
molecules (13,000-57,000  sites/cell after stimulation) (c) Se- 
quential immunoprecipitation confirms that CBRM1/5 recog- 
nizes a structural subset of Mac-1 molecules on neutrophils. 
Lysates that are precleared of the CBRM1/5 epitope contain 
residual Mac-1  molecules that are immunoprecipitated by 
LM2fl but lysates that are precleared of Mac-1  containing 
the LM2/1  epitope  do not contain residual quantities of 
CBRM1/5 precipitable material. (d) Functional studies re- 
veal that despite binding to only 10 % of  the Mac-1 molecules 
on neutrophils stimulated with fMLP, CBRM1/5 (IgG or Fab 
fragments)  inhibits almost completely (>85%)  the  Mac- 
1-dependent adhesion to ICAM-1 and fibrinogen. Additional 
experiments confirmed the blocking capacity of CBRM1/5, 
as  it abrogates  adhesion of ICAM-1 § L  cells  to purified 
Mac-1. 
While several mAbs have been characterized that block 
Mac-l-dependent adhesion to ICAM-1 and fibrinogen (5, 19, 
72, 86), CBRM1/5 is unique, as it recognizes the subset of 
Mac-1 molecules that mediates ligand interaction. CBRM1/5 
maps to the I domain on Mac-1 which appears to contain the 
major recognition site for ICAM-1  and fibrinogen (20a). 
However, not all mAbs that bind to subsets of Mac-1 mole- 
cules recognize functional epitopes.  We have generated a 
second mAb (CBRM1/19, anti-CD18) that binds to activated 
but not resting neutrophils; however, it does not block func- 
tion (Diamond,  M.  S.,  and T.  A.  Springer,  unpublished 
results). The finding of structurally distinct subsets of Mac-1 
molecules  may  explain  why  neutrophils  do  not  show 
significant changes in the redistribution of surface Mac-1 af- 
ter activation with fMLP (16, 70). 
Although activation of neutrophils and monocytes with 
chemotactic factors, cytokines, nucleotides, or phorbol es- 
ters increases the avidity of Mac-1 for several of its ligands 
(3, 4, 19, 59, 72, 84, 86), the molecular basis for this change 
has remained unclear. The quantitative increase in Mac-1 ex- 
pression  on  neutrophils  does  not correlate  directly with 
adhesive functions (11, 49, 80), although, until now, no direct 
evidence has been obtained for a structural change. Studies 
at 4, 25, and 37~  show that an increase in overall Mac-1 ex- 
pression does not induce the CBMR1/5  epitope on neutro- 
phils or monocytes. Similarly, an increase in Mac-1 surface 
expression is  not sufficient to  promote Mac-l-dependent 
adhesion to ICAM-1, fibrinogen, or other ligands ([11, 80] 
and Diamond, M. S., unpublished observations). Adhesion 
to fibrinogen and ICAM-1, and expression of the CBRM1/5 
epitope both require cell stimulation. We suggest that activa- 
tion prompts a  subset of Mac-1  molecules to acquire the 
functionally relevant  CBRM1/5  epitope,  and  to  become 
structurally competent to bind to ICAM-1  and fibrinogen. 
Several mAbs against activation-dependent neoepitopes 
on integrin superfamily members have been recently de- 
scribed, mAbs against the platelet integrin gplIb-IIIa have 
been reported to monitor structural changes that are induced 
either by cellular activation or ligand binding (24).  Indeed, 
the initial evidence for a structural change in integrins came 
from the development of the PAC-1 mAb which recognizes 
gplIb-IIIa on ADP, epinephrine, or thrombin-treated but not 
resting platelets (57, 68). PAC-1 binds to a subset (20-50%) 
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Figure 5.  Flow cytometric anal- 
yses of Mac-1/p150,95 chimeric 
molecules. (A) CHO ceils co-wans- 
fected with the B subunit and the 
indicated Mac-l, p150,95, or chi- 
meric c~ subunit  were stained with 
X63 (nonbinding  control), LM2/1 
(anti-Mac-1  ~x), OKM1 (anti- 
Mac-I e0, BLY6 (anti-plS0,95 ~x), 
and  CBRM1/5 (anti-Mac-I  tx). 
The BLY6 mAb (ascites)  gave a 
higher background staining than 
other  mAbs.  It  sta'med  Mac-I 
transfected  and  untransfected 
CHO cells equivalently (data not 
shown).  (B) Schematic  of the c~ 
subunit, showing the position of 
restriction  sites used for exchange 
of I domains between Mac-1 and 
p150,95. 
Figure 6.  Divalent cations affect expression of Mac-1 mAb epitopes.  (A) Flow cytometry of neutrophils.  Neutrophils  were incubated at 
4~  (resting) and 37~  (fMLP,  10-TM) for 10 min in HBSS that was supplemented by the indicated divalent cation or chelating agent. 
Cells were immunostained  with either a negative control (X63), a mAb to Mac-1 ot subunit (LM2/1), or CBRM1/5. All subsequent washes 
were performed in the presence of the indicated divalent cation or EDTA. Cells were subjected  to immunofluorescent  flow cytometry. 
(B) ELISA of purified Mac-1. Purified Mac-1 was adsorbed to microtiter wells and nonspecific sites were blocked after sequential washes 
with human serum albumin and Tween 20 in the presence of the indicated divalent cation or EDTA (see Methods).  Solid-phase  Mac-1 
was incubated with mAbs (CBRIC1/11, anti-ICAM-1 as control; LM2/1, anti-Mac-1 ~x; CBRM1/5, anti-Mac-1 a) and developed by an ELISA 
with HRP coupled goat anti-mouse IgG. This representative  experiment was performed in triplicate and the bars indicate the standard 
error of the mean. 
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of immunoprecipitates from neu- 
trophil lysates. Iodinated neutro- 
phils  were  lysed  in  1%  Triton 
X-100  and  60#l-aliquots  were 
precipitated  sequentially  with 
Sepharose  coupled  to  LM2/1 
(lane  1),  LM2/1  (lane  2),  and 
finally with CBRM1/5 (lane 3) or 
with CBRM1/5 0ane 4), CBRM1/5 
(lane 5), and finally with LM2/1 
(lane 6) or with mouse IgG (lanes 
7and 10), mouse IgG (lanes 8 and 
11) and finally with LM2/1 (lane 
9)  or with CBRM1/5  (lane 12). 
Material  eluted  from  the  beads 
was run under reducing conditions 
and subjected to autoradiography. 
Molecular weights of protein stan- 
dards (see Methods) are indicated 
to the left. 
Figure 8.  CBRM1/5 mAb blocks binding of Mac-1  to ligand. (A) 
Neutrophil binding to ICAM-1. Neutrophils were allowed to bind 
to purified sICAM-1 in 6-cm Petri dishes for 4 min at room temper- 
ature in the presence of fMLP (10-7M)  after a  10-min preincuba- 
tion with the following mAbs: TS1/22 (anti-LFA-1  a, 1:250 dilution 
of ascites),  LPM19c  (anti-Mac-1  a,  1"250  dilution of ascites), 
CBRM1/5 (anti-Mac-l t~, 25/~g/ml IgG or Fab'2 50/~g/ml of Fab~, 
CBRM1/23 (anti-Mac-l a, 25/~g/ml). (B) The effect of CBRM1/5 
on ICAM-I+L cell adhesion to  purified Mac-1.  ICAM-l+L cells 
were allowed to bind to purified Mac-I in 6-cm Petri dishes for 60 
min at 37~  after a 25-min preincubation with the following mAbs 
with the dishes: TS1/22  (anti-LFA-1  a),  LPM19c (anti-Mac-1 c0, 
CBRMI/5  (anti-Mac-1  or), and  CBRM1/23  (anti-Mac-I  a).  One 
group of ICAM-I+L cells was preincubated with a mAb to ICAM-1 
(R6.5, 30/~g/ml). Data are expressed as the percent cell binding  rela- 
tive to a media control (130 cells/mm2). Datapoints are the average 
of five microscopic fields and the bars indicate the standard error 
of the mean. (C) Dose-dependent inhibition of neutrophil binding 
to fibrinogen by CBRM1/5. Neutrophils were allowed to bind to purified fibrinogen in 6-cm Petri dishes for 4 min at room temperature 
in the presence of fMLP (10-TM) after a  10-min preincubation with increasing concentrations of CBRMI/5 IgG or Fab'. The binding was 
determined by light microscopy (100x) after the unbound cells were removed by serial washes with a Pasteur pipette (see Methods). Data 
are expressed as the percent inhibition  of cell binding relative to a media control (177 cells/mm:). Datapoints are the average of five mi- 
croscopic fields and the bars indicate the standard error of the mean. A-C show representative experiments that were repeated several times. 
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ogen-mediated platelet aggregation (68). Furthermore, CHO 
cells  that  express  gpIIb-IIIa  are  unable  to  bind  soluble 
fibrinogen or the PAC-1 mAb until a structural change has 
occurred (57).  Additional evidence for structural changes 
has come from the characterization of a class of mAbs that 
recognizes ligand-induced binding sites on gpIIb-IIIa (31). 
The generation of mAbs to multiple conformations of gpIIb- 
IIIa suggests that cell activation and ligand binding may effect 
distinct structural changes that facilitate adhesion and medi- 
ate function (32).  Because PAC-1 and CBRM1/5 share simi- 
lar binding properties,  we suggest that the leukocyte inte- 
grins, like the platelet integrins, require similar structural 
changes to promote adhesion. 
Several activation-dependent epitopes on leukocyte inte- 
grins have also been described. The mAb 7E3,  which was 
raised originally against gpIIb-IIIa (13), binds to all Mac-1 
molecules on ADP-stimulated but not resting monocytes or 
monocyte cell lines (2).  Unlike PAC-1 or CBRM1/5,  it has 
no reported functional effects. The NKI-L16 mAb recognizes 
the leukocyte integrin LFA-1 on resting T lymphocytes only 
weakly (45, 79), but binds to T lymphocytes that have been 
activated with phorbol esters, IL-2, or mAbs that cross-link 
CD3. NKI-L16 induces homotypic adhesion of B cell lines 
and T cell clones, and partially restores binding to purified 
ICAM-1 of COS cells that have been transfected with a wild- 
type LFA-1 c~ chain and a defective CD18/~  subunit (38). 
However, the NKI-L16 epitope is not sufficient for cell bind- 
ing since cloned T cells express high levels constitutively but 
do not aggregate spontaneously (79).  The mAb KIM  127 
recognizes the common CD18  /~  subunit of the leukocyte 
integrins and promotes LFA-1- and Mac-l-dependent adhe- 
sive events (61). Binding of this mAb may trigger a confor- 
mational change that mimics activation and increases avidity 
for the ligand. In comparison with these activation-depen- 
dent mAbs against leukocyte integrins, CBRM1/5  appears 
unique in that it binds to a subset of molecules on stimulated 
cells, blocks rather than promotes adhesion, and has an epi- 
tope whose presence correlates with, but does not induce, 
the highly avid form of Mac-1 on neutrophils and monocytes. 
Recent studies have begun to address the structural events 
that effect the increase in avidity. In one model, stimulation 
of cells promotes or alters the divalent cation binding by an 
integrin, and this event triggers the high avidity conforma- 
tion (1, 21, 23). Integrin tx chains contain a region of exten- 
sive homology to the divalent cation binding sites on Ca  2+ 
regulatory proteins (14, 60, 75), and numerous studies dem- 
onstrate a requirement for divalent cations in integrin func- 
tion (1, 9, 23, 27, 33, 39, 41, 50, 52, 63, 73). Furthermore, 
Mn  2+ is reported to stimulate integrin adhesion in the ab- 
sence of other activating signals (1, 23, 27, 33, 41, 73). Sev- 
eral activation-dependent neoepitopes on leukocyte integrins 
have been shown to require the presence of divalent cations. 
Binding of  the mAb 24 (21, 23), which recognizes a common 
determinant on the c~ chain of the three leukocyte integrins, 
requires either Mg  2+ or Mn  2§ but is abolished in the pres- 
ence of Ca  2+. In contrast, expression of the NKI-L16 epi- 
tope  requires  Ca  2+,  as  it is  abolished in the presence  of 
EGTA or EDTA (79).  CBRM1/5  is the first example of an 
activation-specific mAb against an integrin c~ subunit whose 
expression requires divalent cations but is known to bind to 
a region outside the divalent cation binding repeats. EDTA 
abolishes the expression of the CBRM1/5  epitope on both 
cellular and purified Mac-1. On neutrophils, Mn  ~+ increases 
the CBRM1/5 epitope expression in the absence of stimula- 
tion, and thus, may impose structural alterations that mimic 
cell activation (1, 23).  Although these studies suggest that 
divalent cations modulate integrin function, it remains un- 
clear if they are permissive for ligand binding or whether 
divalent cations are  involved actively in the regulation of 
adhesion. 
While leukocyte emigration into inflammatory sites is a 
protective response of  the host defense system against foreign 
pathogens or for tissue repaig,  under some circumstances 
leukocytes can mediate significant degrees of vascular and 
tissue injury. Neutrophils have been implicated in the patho- 
genesis of a number of clinical disorders including adult re- 
spiratory  distress  syndrome, ischemia-reperfusion injury 
after myocardial infarction, vasculitis, and shock (for review 
see [12]). Already, several groups have demonstrated that the 
inflammatory injury mediated by leukocytes can be attenu- 
ated by antibodies against the leukocytes integrins (53, 62, 
69, 81). mAbs like CBRM1/5, which recognize activated but 
not resting leukocytes, could be used clinically to inhibit, 
monitor,  or  deplete  the  highly adhesive  cells  that  effect 
inflammatory injury. 
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